<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464620</url>
  </required_header>
  <id_info>
    <org_study_id>SARC009</org_study_id>
    <nct_id>NCT00464620</nct_id>
  </id_info>
  <brief_title>Trial of Dasatinib in Advanced Sarcomas</brief_title>
  <official_title>A Phase II Trial of Dasatinib in Advanced Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarcoma Alliance for Research through Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sarcoma Alliance for Research through Collaboration</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the response rate and the 6-month progression-free survival rates of
      subjects with advanced sarcoma treated with dasatinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):

      Treatment: Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle.

      Subjects will be seen for interim medical history, physical exam and laboratory studies prior
      to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6
      months and approximately every 3 months thereafter while on treatment.

      A blood sample for collection of specimens with which to later study serum level of Dasatinib
      and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after
      the start of treatment.

      Central collection of archival tumor with which to later study the frequency of expression
      and/or mutation of kinases inhibited by dasatinib will occur.

      Subjects will be followed for approximately every 3 months until 2 years from registration
      and then approximately yearly until 5 years from registration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate: Number of Participants With Objective Tumor Response</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Assessment of objective tumor response for response rate with MRI or CT using Choi criteria: Complete Remission (CR) Complete disappearance of all measurable and evaluable disease for at least 4 weeks; Partial Remission (PR) A 10% or greater decrease from the baseline in the sum of the largest diameters of all measurable target lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Month Progression-free Survival Rate of &quot;Indolent&quot; Sarcomas Treated With Dasatinib</measure>
    <time_frame>At 6 months</time_frame>
    <description>Estimate the 6 month progression-free survival rate of &quot;indolent&quot; sarcomas treated with dasatinib. Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST)</measure>
    <time_frame>6 months</time_frame>
    <description>To estimate the 6 month progression-free survival rate of gastrointestinal stromal tumors (GIST). Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time-to-progression of Subjects With GIST Treated With Dasatinib.</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>To estimate the median time-to-progression of subjects with GIST treated with dasatinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib.</measure>
    <time_frame>At 2 and 5 years</time_frame>
    <description>To estimate the overall survival rates at 2 and 5 years from registration of subjects treated with dasatinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time-to-progression of Subjects With &quot;Indolent&quot; Sarcomas Treated With Dasatinib.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To estimate the median time-to-progression of subjects with &quot;indolent&quot; sarcomas treated with dasatinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype.</measure>
    <time_frame>At 6 months</time_frame>
    <description>To estimate the 6 month progression-free survival rate of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, Malignant fibrous histiocytoma (MFH), rhabdomyosarcoma and MPNST treated with dasatinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time-to-progression of Subjects Enrolled in the Aggressive Subtype.</measure>
    <time_frame>Up to 37 weeks</time_frame>
    <description>To estimate the median time-to-progression of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, MFH, rhabdomyosarcoma and MPNST treated with dasatinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rates at 2 and 5 Years From Registration of Subjects Enrolled in the Aggressive Subtype Treated With Dasatinib.</measure>
    <time_frame>At 2 and 5 years</time_frame>
    <description>To estimate the overall survival rates at 2 and 5 years from registration of subjects enrolled in the aggressive subtype treated with dasatinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uni-dimensional and Bi-dimensional Tumor Size, Tumor Volumes and Tumor Average Density Determined by Computer-aided Automated Detection in a Subset of Subjects With Tumor Predominately Involving the Lung</measure>
    <time_frame>Up to 37 weeks</time_frame>
    <description>To prospectively collect uni-dimensional and bi-dimensional tumor size, tumor volumes and tumor average density determined by computer-aided automated detection in a subset of subjects with tumor predominately involving the lung</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Level of Dasatinib and Inhibition of SRC and/or Focal Adhesion Kinase (FAK) in Peripheral Blood Mononuclear Cells</measure>
    <time_frame>2-4 weeks from start of treatment</time_frame>
    <description>Obtain blood samples to characterize plasma level of dasatinib and inhibition of SRC and/or FAK in peripheral blood mononuclear cells 2 hours after ingestion of drug at 2-4 weeks from the start of treatment if activity of the drug in a sarcoma subtype warrants further study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tumors With Kinase Expression</measure>
    <time_frame>Up to 37 weeks</time_frame>
    <description>Obtain tumor tissue for creation of tissue microarrays to examine the frequency of kinase expression such as SRC and/or FAK in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, Alveolar soft part sarcoma (ASPS), chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma, and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the number of participants who had tissue that was able to generate tissue microarray for kinase expression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Tumors With Mutations in Kinases</measure>
    <time_frame>Up to 37 weeks</time_frame>
    <description>Obtain tumor tissue to examine the frequency of mutations in kinases such as PDGFR in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, ASPS, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the tissue that was able to generate tissue microarray for PDGFR analysis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">366</enrollment>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Malignant Peripheral Nerve Sheath Tumors</condition>
  <condition>Chondrosarcoma</condition>
  <condition>Sarcoma, Ewing's</condition>
  <condition>Sarcoma, Alveolar Soft Part</condition>
  <condition>Chordoma</condition>
  <condition>Epithelioid Sarcoma</condition>
  <condition>Giant Cell Tumor of Bone</condition>
  <condition>Hemangiopericytoma</condition>
  <condition>Gastrointestinal Stromal Tumor (GIST)</condition>
  <arm_group>
    <arm_group_label>Dasatinib, 70 mg, twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>oral agent, continuous dosing, Cycles = 28 days</description>
    <arm_group_label>Dasatinib, 70 mg, twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unresectable, recurrent, or metastatic histologically-confirmed soft tissue or bone
             sarcoma of one of the following subtypes:

               -  Leiomyosarcoma --* NO LONGER ELIGIBLE*

               -  Liposarcoma--* NO LONGER ELIGIBLE*

               -  Malignant fibrous histiocytoma (MFH)/pleomorphic undifferentiated sarcoma--* NO
                  LONGER ELIGIBLE*

               -  Rhabdomyosarcoma --* NO LONGER ELIGIBLE*

               -  Malignant peripheral nerve sheath tumor (MPNST) --* NO LONGER ELIGIBLE*

               -  Osteosarcoma (skeletal or extraosseous)--* NO LONGER ELIGIBLE*

               -  Ewing's --* NO LONGER ELIGIBLE*

               -  Chondrosarcoma

               -  Alveolar soft part sarcoma

               -  Chordoma

               -  Epithelioid sarcoma

               -  Giant cell tumor of bone

               -  Hemangiopericytoma/solitary fibrous tumor

               -  Gastrointestinal Stromal Tumor (GIST) --* NO LONGER ELIGIBLE*

          2. Documentation that subjects with leiomyosarcoma, liposarcoma, osteosarcoma, Ewing's,
             MPNST, rhabdomyosarcoma or MFH have received, not been eligible for or refused at
             least one prior chemotherapy regimen before participation in the dasatinib study.
             Subjects with GIST must have received or been intolerant to imatinib; prior treatment
             with other agents including sunitinib is not required.Neoadjuvant/adjuvant
             chemotherapy qualifies as prior therapy.

          3. Subjects must have unidimensionally measurable lesion(s) either by x-ray, computed
             tomography (CT), magnetic resonance imaging (MRI) or physical examination documented
             within 30 days prior to registration.

          4. Prior radiation will be allowed. More than two weeks should have elapsed since the
             administration of the last fraction of radiation therapy, and subjects must have
             recovered from grade 2 or higher associated toxicities. Measurable lesions, which are
             selected as target lesions, must be outside previously radiated fields or have
             documented progression no sooner than 6 weeks after completion of radiation.

          5. More than 2 weeks must have elapsed since the subject has received any prior systemic
             chemotherapy (6 weeks for mitomycin C), and the patient should have recovered from
             toxicities to the baseline prior to the last course of chemotherapy.

          6. Adequate hematologic function within 14 days prior to registration.

          7. Prothrombin Time (PT) (or INR) and Partial Thromboplastin Time (PTT) ≤ 1.5 times the
             institutional upper limit of normal (ULN) within 14 days prior to registration.

          8. Serum creatinine ≤ 2.0 times the institutional ULN within 14 days prior to
             registration.

          9. Serum magnesium, potassium and adjusted (or ionized) calcium ≥ the institutional lower
             limit of normal (LLN). (Supplementation of electrolytes prior to screening is
             allowed).

         10. Left ventricular ejection fraction ≥ 45% measured by echocardiogram or multiple gated
             acquisition (MUGA) within 30 days prior to registration (but must be performed after
             the last dose of an anthracycline) for subjects who have received an anthracycline
             (e.g. doxorubicin, epirubicin) or have a medical history of cardiac disease. The
             measurement of left ventricular ejection fraction is not required of subjects whom
             have not received cardiotoxic chemotherapy (e.g. anthracycline) and do not have a
             medical history of cardiac disease.

         11. Sexually active women and men of childbearing potential must agree to use an effective
             method of birth control during the course of the study and for up to 3 months
             following the last dose of the study drug, in a manner such that risk of pregnancy is
             minimized. Surgical sterilization, intrauterine device or barrier method (e.g. condom
             and/or diaphragm with spermicidal agents) are acceptable forms of birth control.

         12. Women of childbearing potential must have a negative pregnancy test (urine or serum)
             within 7 days prior to treatment. A pregnancy test is not required for registration.
             Women who have not menstruated for more than 2 years will be considered
             postmenopausal, thus not of childbearing potential.

         13. Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2.

         14. Weight ≥ 50 kg because there is limited experience with dasatinib in subjects weighing
             less than 50 kg.

         15. ≥13 years of age Minors will be required to sign an assent document prior to
             treatment.

         16. Subjects must be able to swallow whole tablets.

         17. Subjects must be informed of the investigational nature of the study and provide
             written, informed consent and authorization to release protected health information
             using a document(s) approved by the investigator's institution.

         18. A paraffin block, either from a previous surgery or recent biopsy, should be available
             for correlative studies. If a block of tumor is not available, at least 8 unstained
             slides of tumor sample, 1 H&amp;E and three (3) 15 micron-thick sections in an eppendorf
             tube for DNA extraction from a representative portion of the sarcoma may be
             substituted after discussion with and approval from the study Principal Investigator.

        Exclusion Criteria:

          1. Subjects who are curable by conventional multidisciplinary management.

          2. Subjects with symptomatic central nervous system metastasis.

          3. Women who are pregnant or nursing/breastfeeding.

          4. History of significant bleeding disorder unrelated to cancer, including:

               -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)

               -  Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor
                  VIII antibodies)

          5. Subjects currently taking medications that inhibit platelet function (i.e., aspirin,
             dipyridamole, epoprostenol, eptifibatide, clopidogrel, cilostazol, abciximab,
             ticlopidine, and any non-steroidal anti-inflammatory drug) because of a potential
             increased risk of bleeding from dasatinib.

          6. Subjects currently taking anticoagulants (warfarin, heparin/low molecular weight
             heparin [e.g., danaparoid, dalteparin, tinzaparin, enoxaparin]) because of a potential
             increased risk of bleeding from dasatinib.

          7. Diagnosis of unstable angina or myocardial infarction within 6 months of study entry.

          8. Subjects currently taking one or more of the following drugs that are generally
             accepted to have a risk of causing Torsades de Pointes:

               -  Quinidine, procainamide, disopyramide

               -  Amiodarone, sotalol, ibutilide, dofetilide

               -  Erythromycins, clarithromycin

               -  Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide

               -  Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone,
                  halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.

          9. Diagnosed or suspected congenital long QT syndrome.

         10. Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (&gt; 450 msec)
             within 30 days prior to study registration.

         11. Subjects unable or unwilling to suspend treatment with bisphosphonates for at least
             the first 8 weeks of treatment with study drug because of the risk of hypocalcemia
             caused by dasatinib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Schuetze, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Outpatient Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute at Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Cancer Center</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hematology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sarctrials.org</url>
    <description>SARC Website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 20, 2007</study_first_submitted>
  <study_first_submitted_qc>April 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2007</study_first_posted>
  <results_first_submitted>August 3, 2018</results_first_submitted>
  <results_first_submitted_qc>October 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2018</results_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dasatinib</keyword>
  <keyword>Rhabdomyosarcoma</keyword>
  <keyword>Malignant peripheral nerve sheath tumor</keyword>
  <keyword>Chondrosarcoma</keyword>
  <keyword>Ewing's</keyword>
  <keyword>Alveolar soft part sarcoma (ASPS)</keyword>
  <keyword>Chordoma</keyword>
  <keyword>Epithelioid sarcoma</keyword>
  <keyword>Giant cell tumor of bone</keyword>
  <keyword>Hemangiopericytoma/solitary fibrous tumor</keyword>
  <keyword>Gastrointestinal Stromal Tumor (GIST)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Chordoma</mesh_term>
    <mesh_term>Giant Cell Tumors</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
    <mesh_term>Hemangiopericytoma</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Giant Cell Tumor of Bone</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>50 patients with GIST were enrolled between June 2008 and December 2009 and 48 were evaluable for response. Between May 2007 and May 2009, 200 patients with advanced, high-grade sarcoma were enrolled into the aggressive subtype for this study. 116 patients were registered beginning in July 2007 to the indolent subtype for this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GIST: Dasatinib, 70 mg, Twice Daily</title>
          <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
        </group>
        <group group_id="P2">
          <title>Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily</title>
          <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
        </group>
        <group group_id="P3">
          <title>Indolent Subtype: Dasatinib, 70 mg, Twice Daily</title>
          <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48">48 patients were evaluable.</participants>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible sarcoma subtype</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of prohibited concomitant medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>116 subjects enrolled in the Indolent subtype, however 109 subjects began treatment. Baseline characteristics for the Indolent subtype were based off of 109 subjects on treatment. This explains the discrepancy between the Participant Flow and the Overall Number of Baseline Participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib, 70 mg, Twice Daily</title>
          <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="359"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The baseline measurements are categorized by the three different subtypes from the protocol (aggressive, indolent and GIST).</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Aggressive subtype</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="14.8" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="19" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indolent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="22" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The baseline measurements are categorized by the three different subtypes from the protocol (aggressive, indolent and GIST).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Aggressive subtype</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indolent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>The baseline measurements are categorized by the three different subtypes from the protocol (aggressive, indolent and GIST).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Aggressive subtype</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indolent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate: Number of Participants With Objective Tumor Response</title>
        <description>Assessment of objective tumor response for response rate with MRI or CT using Choi criteria: Complete Remission (CR) Complete disappearance of all measurable and evaluable disease for at least 4 weeks; Partial Remission (PR) A 10% or greater decrease from the baseline in the sum of the largest diameters of all measurable target lesions.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>116 subjects enrolled in the Indolent subtype, however 109 subjects began treatment. 50 patients enrolled in the GIST subtype, however 48 patients were evaluable. This explains the discrepancy between Overall Number of Participants Analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GIST: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O3">
            <title>Indolent Subtype: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate: Number of Participants With Objective Tumor Response</title>
          <description>Assessment of objective tumor response for response rate with MRI or CT using Choi criteria: Complete Remission (CR) Complete disappearance of all measurable and evaluable disease for at least 4 weeks; Partial Remission (PR) A 10% or greater decrease from the baseline in the sum of the largest diameters of all measurable target lesions.</description>
          <population>116 subjects enrolled in the Indolent subtype, however 109 subjects began treatment. 50 patients enrolled in the GIST subtype, however 48 patients were evaluable. This explains the discrepancy between Overall Number of Participants Analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Month Progression-free Survival Rate of &quot;Indolent&quot; Sarcomas Treated With Dasatinib</title>
        <description>Estimate the 6 month progression-free survival rate of &quot;indolent&quot; sarcomas treated with dasatinib. Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass.</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Indolent Subtypes: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Progression-free Survival Rate of &quot;Indolent&quot; Sarcomas Treated With Dasatinib</title>
          <description>Estimate the 6 month progression-free survival rate of &quot;indolent&quot; sarcomas treated with dasatinib. Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST)</title>
        <description>To estimate the 6 month progression-free survival rate of gastrointestinal stromal tumors (GIST). Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GIST: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST)</title>
          <description>To estimate the 6 month progression-free survival rate of gastrointestinal stromal tumors (GIST). Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time-to-progression of Subjects With GIST Treated With Dasatinib.</title>
        <description>To estimate the median time-to-progression of subjects with GIST treated with dasatinib.</description>
        <time_frame>Up to 30 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GIST: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time-to-progression of Subjects With GIST Treated With Dasatinib.</title>
          <description>To estimate the median time-to-progression of subjects with GIST treated with dasatinib.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib.</title>
        <description>To estimate the overall survival rates at 2 and 5 years from registration of subjects treated with dasatinib.</description>
        <time_frame>At 2 and 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GIST: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O2">
            <title>Indolent Subtype: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib.</title>
          <description>To estimate the overall survival rates at 2 and 5 years from registration of subjects treated with dasatinib.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 years overall survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 years overall survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time-to-progression of Subjects With &quot;Indolent&quot; Sarcomas Treated With Dasatinib.</title>
        <description>To estimate the median time-to-progression of subjects with &quot;indolent&quot; sarcomas treated with dasatinib.</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Indolent Subtype: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time-to-progression of Subjects With &quot;Indolent&quot; Sarcomas Treated With Dasatinib.</title>
          <description>To estimate the median time-to-progression of subjects with &quot;indolent&quot; sarcomas treated with dasatinib.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="3.7" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype.</title>
        <description>To estimate the 6 month progression-free survival rate of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, Malignant fibrous histiocytoma (MFH), rhabdomyosarcoma and MPNST treated with dasatinib.</description>
        <time_frame>At 6 months</time_frame>
        <population>The numbers analyzed in one or more rows are different because they are broken up by cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype.</title>
          <description>To estimate the 6 month progression-free survival rate of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, Malignant fibrous histiocytoma (MFH), rhabdomyosarcoma and MPNST treated with dasatinib.</description>
          <population>The numbers analyzed in one or more rows are different because they are broken up by cohorts.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leiomyosarcoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteosarcoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhabdomyosarcoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ewing's Sarcoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liposarcoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPNST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time-to-progression of Subjects Enrolled in the Aggressive Subtype.</title>
        <description>To estimate the median time-to-progression of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, MFH, rhabdomyosarcoma and MPNST treated with dasatinib.</description>
        <time_frame>Up to 37 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time-to-progression of Subjects Enrolled in the Aggressive Subtype.</title>
          <description>To estimate the median time-to-progression of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, MFH, rhabdomyosarcoma and MPNST treated with dasatinib.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.9" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rates at 2 and 5 Years From Registration of Subjects Enrolled in the Aggressive Subtype Treated With Dasatinib.</title>
        <description>To estimate the overall survival rates at 2 and 5 years from registration of subjects enrolled in the aggressive subtype treated with dasatinib.</description>
        <time_frame>At 2 and 5 years</time_frame>
        <population>The number analyzed in one or more rows differs from overall number because the rows are broken down into cohorts. The counts in the categories will not add up to the number analyzed, because those numbers represent number of participants that have reached overall survival at 2 and 5 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rates at 2 and 5 Years From Registration of Subjects Enrolled in the Aggressive Subtype Treated With Dasatinib.</title>
          <description>To estimate the overall survival rates at 2 and 5 years from registration of subjects enrolled in the aggressive subtype treated with dasatinib.</description>
          <population>The number analyzed in one or more rows differs from overall number because the rows are broken down into cohorts. The counts in the categories will not add up to the number analyzed, because those numbers represent number of participants that have reached overall survival at 2 and 5 years.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ewing's Sarcoma : 2 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ewing's Sarcoma : 5 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leiomyosarcoma : 2 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leiomyosarcoma : 5 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liposarcoma : 2 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liposarcoma : 5 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPNST : 2 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPNST : 5 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteosarcoma : 2 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteosarcoma : 5 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhabdomyosarcoma : 2 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhabdomyosarcoma : 5 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPS : 2 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UPS : 5 year overall survival rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uni-dimensional and Bi-dimensional Tumor Size, Tumor Volumes and Tumor Average Density Determined by Computer-aided Automated Detection in a Subset of Subjects With Tumor Predominately Involving the Lung</title>
        <description>To prospectively collect uni-dimensional and bi-dimensional tumor size, tumor volumes and tumor average density determined by computer-aided automated detection in a subset of subjects with tumor predominately involving the lung</description>
        <time_frame>Up to 37 weeks</time_frame>
        <population>This data was not collected because the imaging software and work station was not obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>GIST: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O3">
            <title>Indolent Subtype: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Uni-dimensional and Bi-dimensional Tumor Size, Tumor Volumes and Tumor Average Density Determined by Computer-aided Automated Detection in a Subset of Subjects With Tumor Predominately Involving the Lung</title>
          <description>To prospectively collect uni-dimensional and bi-dimensional tumor size, tumor volumes and tumor average density determined by computer-aided automated detection in a subset of subjects with tumor predominately involving the lung</description>
          <population>This data was not collected because the imaging software and work station was not obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Level of Dasatinib and Inhibition of SRC and/or Focal Adhesion Kinase (FAK) in Peripheral Blood Mononuclear Cells</title>
        <description>Obtain blood samples to characterize plasma level of dasatinib and inhibition of SRC and/or FAK in peripheral blood mononuclear cells 2 hours after ingestion of drug at 2-4 weeks from the start of treatment if activity of the drug in a sarcoma subtype warrants further study.</description>
        <time_frame>2-4 weeks from start of treatment</time_frame>
        <population>Evaluation of blood levels of drug was not performed because there was insufficient activity and the level of activity did not warrant further study.</population>
        <group_list>
          <group group_id="O1">
            <title>GIST: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O2">
            <title>Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O3">
            <title>Indolent Subtype: Dasatinib, 70 mg, Twice Daily</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Level of Dasatinib and Inhibition of SRC and/or Focal Adhesion Kinase (FAK) in Peripheral Blood Mononuclear Cells</title>
          <description>Obtain blood samples to characterize plasma level of dasatinib and inhibition of SRC and/or FAK in peripheral blood mononuclear cells 2 hours after ingestion of drug at 2-4 weeks from the start of treatment if activity of the drug in a sarcoma subtype warrants further study.</description>
          <population>Evaluation of blood levels of drug was not performed because there was insufficient activity and the level of activity did not warrant further study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tumors With Kinase Expression</title>
        <description>Obtain tumor tissue for creation of tissue microarrays to examine the frequency of kinase expression such as SRC and/or FAK in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, Alveolar soft part sarcoma (ASPS), chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma, and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the number of participants who had tissue that was able to generate tissue microarray for kinase expression.</description>
        <time_frame>Up to 37 weeks</time_frame>
        <population>The overall number of participants analyzed demonstrates the number of participants whose tumor samples received. The results illustrate the tissue that was able to generate tissue microarray for SRC and FAK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Osteosarcoma</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O2">
            <title>Leiomyosarcoma</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O3">
            <title>MFH/Undifferentiated Pleomorphic Sarcoma</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumors With Kinase Expression</title>
          <description>Obtain tumor tissue for creation of tissue microarrays to examine the frequency of kinase expression such as SRC and/or FAK in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, Alveolar soft part sarcoma (ASPS), chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma, and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the number of participants who had tissue that was able to generate tissue microarray for kinase expression.</description>
          <population>The overall number of participants analyzed demonstrates the number of participants whose tumor samples received. The results illustrate the tissue that was able to generate tissue microarray for SRC and FAK analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Tumors With Mutations in Kinases</title>
        <description>Obtain tumor tissue to examine the frequency of mutations in kinases such as PDGFR in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, ASPS, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the tissue that was able to generate tissue microarray for PDGFR analysis.</description>
        <time_frame>Up to 37 weeks</time_frame>
        <population>The overall number of participants analyzed demonstrates the number of participants whose tumor samples were received. The results illustrate the tissue that was able to generate tissue microarray for PDGFR analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Osteosarcoma</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O2">
            <title>Leiomyosarcoma</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
          <group group_id="O3">
            <title>MFH/Undifferentiated Pleomorphic Sarcoma</title>
            <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumors With Mutations in Kinases</title>
          <description>Obtain tumor tissue to examine the frequency of mutations in kinases such as PDGFR in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, ASPS, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the tissue that was able to generate tissue microarray for PDGFR analysis.</description>
          <population>The overall number of participants analyzed demonstrates the number of participants whose tumor samples were received. The results illustrate the tissue that was able to generate tissue microarray for PDGFR analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GIST, Aggressive, Indolent Subtypes</title>
          <description>Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
Dasatinib: oral agent, continuous dosing, Cycles = 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood-other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Distention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage: lower GI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage: upper GI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Obstruction: small bowel</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Obstruction: stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Pain: abdomen</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Ulcer: colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI- other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage- abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage- esophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage- rectum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage- stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms-other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Death, NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Disease progression, NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhage-other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Edema- limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gait/walking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Unk ANC: blood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lung infection, 0-2 ANC: bronchus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lung Infection, 3-4 ANC: bronchus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lung Infection, Unk ANC: lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Coagulation-other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Musculo. Pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Neuropathy- sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>GU Hemorrhage: urinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GU Hemorrhage: vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GU Infection, 0-2 ANC: urinary tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GU Infection, Unk ANC: ureter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GU Pain: kidney</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive pain: pelvis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pelvis pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lung Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pulmonary-other</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology- other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="314" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="19" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="103" subjects_affected="70" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpaitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Prolonged QTc</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cardiac- Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear- Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ocular- Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="99" subjects_affected="73" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="93" subjects_affected="81" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="38" subjects_affected="36" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Pain: abdomen</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Distention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Gastrointestinal- Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Hemorrhage</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="50" subjects_affected="34" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="144" subjects_affected="113" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pain- Other</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GU Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GI Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Eye Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Elevated PTT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="45" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="25" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Elevated Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Elevated serum bilirubin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Low serum bicarbonate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Elevated lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="100" subjects_affected="67" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor Pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="68" subjects_affected="52" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>CNS Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Involuntary movement</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Urine color change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Bladder spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Renal - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Ureter obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>GU Hemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvis pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="55" subjects_affected="45" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="78" subjects_affected="56" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="60" subjects_affected="43" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pulmonary- Other</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Lung Pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="64" subjects_affected="52" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Skin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Dermatology- Other</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
              <event>
                <sub_title>Vascular- Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="355"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>SARC</name_or_title>
      <organization>SARC</organization>
      <phone>(734) 930-7600</phone>
      <email>sarc@sarctrials.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

